In January 2021, the Company completed a follow-on public offering of 3,450,000 shares of common stock, which included the underwriters’ option to purchase an additional 450,000 shares of common stock. The offering resulted in net proceeds to the Company of approximately $221.4 million, after deducting fees and estimated offering expenses payable by the Company.
In June 2021, the Company completed a follow-on public offering of 4,600,000 shares of its common stock, which included the full exercise of the underwriters’ option to purchase an additional 600,000 shares of common stock. The offering resulted in net proceeds to the Company of approximately $327.0 million, after deducting fees and estimated offering expenses payable by the Company.
2019 ATM Program
In July 2019, the Company entered into a $400.0 million ATM program (the “2019 ATM Program”) through which the Company, from time to time, sold shares of common stock.
During the fourth quarter of 2019, the Company entered into forward sale agreements in connection with the 2019 ATM Program to sell an aggregate of 2,003,118 shares of common stock. Additionally, during the first quarter of 2020, the Company entered into forward sale agreements in connection with the 2019 ATM Program to sell an aggregate of 3,169,754 shares of common stock. During 2020, the Company settled all forward sale agreements under the 2019 ATM Program realizing net proceeds of $359.5 million.
The 2019 ATM Program was terminated simultaneously with the establishment of the 2020 ATM Program, which is discussed below. As a result, no future issuances will occur under the 2019 ATM Program.
2020 ATM Program
In March 2020, the Company entered into a new $400.0 million ATM program (the “2020 ATM Program”) through which the Company, from time to time, may sell shares of common stock. In addition to selling shares of common stock, the Company entered into forward sale agreements through the 2020 ATM Program, as described below.
During 2020, the Company entered into forward sale agreements to sell an aggregate of 3,334,056 shares of common stock. During 2020, the Company settled 204,074 shares of these forward sale agreements, realizing net proceeds of $12.5 million. During the first six months of 2021, the Company settled 742,860 shares of these forward sale agreements, realizing net proceeds of $46.8 million. The Company is required to settle the remaining outstanding shares of common stock under the 2020 ATM Program by various dates between July 2021 and December 2021.
The 2020 ATM Program was terminated simultaneously with the establishment of the 2021 ATM Program, which is discussed below. As a result, no future issuances will occur under the 2020 ATM Program.
2021 ATM Program
In February 2021, the Company entered into a new $500.0 million ATM program (the “2021 ATM Program”) through which the Company, from time to time, may sell shares of common stock. In addition to selling shares of common stock, the Company has entered into forward sale agreements through the 2021 ATM Program, as described below.
During the first six months of 2021, the Company entered into forward sale agreements to sell an aggregate of 1,550,666 shares of common stock. The Company has not settled any shares of these forward sale agreements as of June 30, 2021. The Company is required to settle the remaining outstanding shares of common stock under the 2021 ATM Program by various dates between March 2022 and June 2022.
After considering the 1,550,666 shares of common stock subject to forward sale agreements issued under the 2021 ATM Program, the Company had approximately $391.7 million of availability remaining under the 2021 ATM Program as of June 30, 2021.